Ro-3306 - Moligand™, 10mM in DMSO , Inhibitor of cyclin dependent kinase 1;Inhibitor of cyclin dependent kinase 2;Inhibitor of cyclin dependent kinase 5, CAS No.872573-93-8, Inhibitor of cyclin dependent kinase 1;Inhibitor of cyclin dependent kinase 2;Inhibitor of cyclin dependent kinase 5

CAS: 872573-93-8 Cat. No.: R408011 Fórmula: C₁₈H₁₃N₃OS₂ Peso molecular: 351.44

GRADE & PURITY Moligand™, 10mM in DMSO

Synonyms

(Z)-5-(quinolin-6-ylmethylene)-2-(thiophen-2-ylmethylamino)thiazol-4(5H)-one

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Visão geral

Information

Ro-3306 RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K i of 20 nM, >15-fold selectivity against a diverse panel of human kinases. RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis .
In vitro

RO-3306 inhibits CDK1/cyclin B1, CDK1/cyclin A, CDK2/cyclin E, and CDK4/cyclin D activity with Ki of 35 nM, 110 nM, 340 nM, and over 2000 nM, respectively. Treatment of HCT116, SW480, and HeLa cells with RO-3306 for 20 h leads to a complete block of the cell cycle in the G2/M phase. The proliferation of both HCT116 and SW480 is effectively blocked by RO-3306. RO-3306 appears to be more proapoptotic in cancer cells (HCT116 and SW480) than nontumorigenic cells (MCF 10A and MCF 12A). RO-3306 effectively arrests oocyte maturation at a concentration of 10 μM.

In vivo

Cell Data

cell lines：MM cell lines, patient MM cells, and PBMCs

Concentrations：20 μM

Incubation Time：72 h

Powder Purity:≥98%

Specifications

Sinónimos

(Z)-5-(quinolin-6-ylmethylene)-2-(thiophen-2-ylmethylamino)thiazol-4(5H)-one

Especificações e pureza

Moligand™, 10mM in DMSO

Mecanismos bioquímicos e fisiológicos

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases. RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis.

Condições de armazenamento de armazenamento

Store at -80°C

Enviado em

Dry ice packs + Cold packs

Este produto requer transporte de cadeia fria. Serviços terrestres e outros serviços econômicos não estão disponíveis.

Grau

Moligand™

Tipo de ação

INHIBITOR

Mecanismo de ação

Inhibitor of cyclin dependent kinase 1;Inhibitor of cyclin dependent kinase 2;Inhibitor of cyclin dependent kinase 5

Nomes e identificadores

• SMILES isoméricas: C1=CC2=C(C=CC(=C2)/C=C\3/C(=O)NC(=NCC4=CC=CS4)S3)N=C1
• Peso molecular: 351.44
• Reaxy-Rn: 40639142
• Reaxys-RN_link_address: https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=40639142&ln=

Alvos associados (humanos)

CDK1 Tchem Cyclin-dependent kinase 1 (2 Activities)

Discover Target: CDK1

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Application Protocols

Not specified for this item; refer to CoA/Spec Sheet.

Only product-specific, vendor-verified protocols belong here. For general, literature-based example workflows (e.g., cell-cycle synchronization using CDK1 inhibition), please consult peer-reviewed publications and adapt to your system.

Biological Roles

Contextual, literature-based summary (for research use only):

• Primary role: Ro-3306 is commonly used as a selective, ATP-competitive CDK1 inhibitor, enabling temporal control of the G2/M transition for cell-cycle synchronization in mammalian systems (literature).
• Mechanism context: By occupying the ATP-binding site of CDK1, Ro-3306 reduces phosphorylation of CDK1 substrates, maintaining cells in G2. Washout typically restores kinase activity and promotes synchronous mitotic entry (literature).
• Utility in pathways: Supports studies of DNA damage checkpoints, mitotic spindle assembly, and proteostasis linked to cell-cycle control. It can be paired with other modulators (e.g., CDK4/6 inhibitors or nocodazole) to stage cells at defined phases (literature).
• Selectivity context: Frequently cited as more selective for CDK1 over CDK2 and other CDKs, though off-targets may appear at higher concentrations—necessitating proper controls and concentration–response confirmation (literature).
• Assay considerations: Validate the biochemical/phenotypic effects with orthogonal readouts (e.g., phospho-histone H3, cyclin levels) and include vehicle controls.

Item-specific target data and potencies are not provided here; consult the CoA and peer-reviewed literature for quantitative parameters.

Buffer Applications

Not a buffering reagent. Ro-3306 does not act as a pH buffer or buffer component under typical laboratory use. For biological assays, it is dissolved in DMSO and then diluted into the appropriate assay or culture buffer/media. See Solvent Selection and Storage & Reconstitution for practical guidance.

Green Alternatives

Ro-3306 is a specialized bioactive probe; “green” considerations relate mainly to solvent and handling rather than substitution of the active compound.

Greener handling choices (literature/context):

• Minimize DMSO volume: Keep final assay DMSO at or below the lowest tolerated concentration (often ≤0.1–0.2% v/v) to reduce organic load.
• Aqueous-compatible vehicles: Where feasible, evaluate co-solvent systems (e.g., small % ethanol with surfactant) that maintain solubility while limiting DMSO—after confirming no impact on biology.
• Micro-volume operations: Use high-concentration stocks and acoustic/low-dead-volume dispensing to reduce solvent waste in screening.
• Waste management: Segregate halogen-free, non-chlorinated solvent waste; adopt solvent recovery where possible.

Illustrative comparison (general):

• DMSO (benchmark): Excellent solvency, high boiling point, miscible with water; potential biological effects at higher %.
• Ethanol: Renewable source, biodegradable, better EHS profile; may have lower solvency and variable cell tolerance.
• Aqueous buffers: Greenest medium but often insufficient solubility; requires careful formulation to avoid precipitation.

Item-specific greener substitutes for the active compound are not applicable due to its target selectivity role.

Pharmaceutical Uses

This product is supplied strictly for research use only. No clinical or therapeutic claims are made.

Formulation/technical context (non-clinical, literature):

• Reference/positive control compound: Often used in discovery biology for benchmarking CDK1-related pharmacology in biochemical and cellular assays.
• HTS/HCS compatibility: Amenable to plate-based screening workflows using DMSO stocks and low final solvent percentages.
• Stability handling: Aliquot and store frozen to maintain integrity over extended campaigns; monitor for potency drift via periodic QC assays.

Pharmacopeial status, excipient roles, and drug product applications: Not applicable/not specified for this item.

Physical Properties

Item-specific specifications:

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular formula / MW: Not specified for this item; refer to CoA/Spec Sheet.

General/literature guidance for Ro-3306 (non-spec values):

• Physical state: Typically a solid small molecule (literature).
• Solubility: Readily soluble in polar aprotic organic solvents such as DMSO and DMF; sparingly soluble in aqueous buffers without co-solvent (literature).
• Aqueous handling: Common practice is to prepare concentrated DMSO stock solutions (e.g., 10–50 mM) and dilute into assay media to low micromolar working concentrations, maintaining final DMSO ≤0.1–0.5% v/v (literature).
• pKa/logP, BP/MP, density, refractive index: Not specified for this item; consult literature databases or the CoA if available.

Notes:

• If precipitate forms on aqueous dilution, slight warming, sonication, or incremental addition of DMSO may help, provided this is compatible with the biological system (literature).
• Always verify actual item-specific properties on the provided Certificate of Analysis (CoA).

Quality and Grades

• Grade/Purity: Moligand™ (Aladdin).

What Moligand™ generally implies (program-level context):

• Designed for discovery screening and chemical biology workflows, emphasizing reliable identity and purity suitable for target validation, phenotypic screening, and probe studies.
• Compounds are typically provided with traceability and are amenable to high-throughput plate formatting and DMSO stock preparation (program-level description).

Item-specific analytical details:

• Purity percentage, residual solvents, water content, stabilizers, trace metals, UV cutoffs: Not specified for this item; refer to CoA/Spec Sheet.
• Identity confirmation methods (e.g., NMR/LC-MS/HPLC): Not specified for this item; refer to CoA/Spec Sheet.

Practical implications:

• For screening and mechanistic studies, confirm purity and identity data on the batch CoA prior to critical experiments. If using in quantitative biology/chemistry, consider verifying potency and purity in-house (e.g., orthogonal LC-MS) and documenting DMSO stock concentration by UV or qNMR as appropriate.

Reaction and Applications

This product is a bioactive small molecule used primarily as a research probe, not as a synthetic reagent.

Applications (literature, non-clinical):

• Cell-cycle research tool: Ro-3306 is widely used to achieve reversible G2/M boundary arrest via selective inhibition of CDK1, enabling synchronization protocols in mammalian cells and controlled release into mitosis (literature).
• Mechanistic studies: Dissects CDK1-dependent phosphorylation events in vitro and in cells; supports target validation and pathway analysis (literature).
• Phenotypic screening: Serves as a reference compound/positive control in kinase-focused panels and cell-cycle phenotypic assays (literature).

Practical tips (literature):

• Prepare concentrated DMSO stocks (e.g., 10–50 mM) and store frozen as aliquots to minimize freeze–thaw.
• Typical cell-based working concentrations reported are in the low micromolar range; optimize per cell line and endpoint.
• Confirm target engagement using orthogonal readouts (e.g., phospho-substrate levels, cell-cycle profiling by flow cytometry).

Note: No synthetic/named reactions are directly relevant because Ro-3306 is used as a biological probe rather than a building block. For chemistry-focused needs, see sections on Solvent Selection and Storage & Reconstitution.

Reaction Conditions

This product is not used as a reagent in chemical reactions; thus, classical reaction-condition guidance (solvent, temperature, catalysts) is not applicable.

Assay/usage conditions (literature, for context only):

• Stock solutions: Prepare in DMSO at 10–50 mM; filter if needed (0.22 µm) to remove particulates.
• Cell-based assays: Working concentrations often reported in the 1–10 µM range, with exposure times from 4–20 hours for G2/M synchronization, followed by washout to trigger mitotic entry (optimize per cell line).
• Biochemical assays: Maintain consistent DMSO across wells (commonly 0.1–1% v/v); include ATP competition controls to confirm mode of inhibition.
• Controls: Include vehicle controls and, where possible, orthogonal CDK1 inhibitors or inactive analogs to confirm on-target effects.

Note: Quantitative, item-specific potency and kinetics are not provided; check batch documentation and peer-reviewed sources for exact numbers.

Safety and Handling

GHS/SDS status for this item:

• Signal word / H-statements / Pictograms / Classification: Not specified for this item; refer to the SDS for authoritative safety information.

General laboratory safety guidance (good practice):

• PPE: Wear lab coat, appropriate chemically resistant gloves, and safety glasses. Handle powders/solutions in a fume hood to avoid inhalation or aerosol exposure.
• Avoid exposure: Prevent contact with skin, eyes, and clothing. Avoid inhalation of dust or vapors.
• First aid (overview): In case of skin or eye contact, rinse with plenty of water for several minutes and seek medical attention as needed. If inhaled, move to fresh air; if ingested, rinse mouth. Always follow your institution’s SOPs and SDS guidance.
• Incompatibilities: Strong oxidizers and strong acids/bases may degrade organic inhibitors; segregate accordingly (general chemical practice).
• Spill response: Absorb small spills with inert material (e.g., vermiculite), collect in labeled container for disposal.
• Waste disposal: Dispose as organic laboratory waste in accordance with local regulations and institutional policies.

Shipping and stability:

• Shipped on dry ice + cold packs per product data; maintain the cold chain. Store at the specified ultra-low temperature on receipt.

Solvent Selection

Ro-3306 is a hydrophobic, heteroatom-bearing small molecule tool compound; solvent choice strongly affects handling and assay performance.

• Primary stock solvent (literature): DMSO is preferred due to high solubility and compatibility with cell-based assays at low final percentages.
• Alternative solvents (literature): DMF and ethanol can dissolve many kinase inhibitors, but DMF may be less biocompatible; ethanol tolerance varies by cell type.
• Aqueous media: Direct dissolution in water or buffer is generally poor; dilute from a concentrated DMSO stock to achieve target micromolar levels.
• Polarity/dielectric (context): DMSO (ε ≈ 47, highly polar aprotic) effectively solvates diverse heteroaromatic inhibitors; ethanol (ε ≈ 24) offers intermediate polarity with better biological tolerance in some systems (literature).

When to choose what:

• Cellular assays: DMSO stocks, final DMSO ≤0.1–0.5% v/v. Validate vehicle controls.
• Biochemical enzyme assays: DMSO stocks; ensure assay buffer contains sufficient detergent or carrier protein if nonspecific adsorption is observed.
• Incompatible systems: If DMSO must be minimized, consider co-solvent approaches (e.g., PEG400:water mixtures) after compatibility testing (literature).

Item-specific solubility limits are not provided; confirm empirically and refer to the CoA/Spec Sheet.

Storage and Reconstitution

Item-specific conditions:

• Storage: Store at -80°C (per product data).
• Shipping: Shipped on dry ice packs + cold packs; maintain the cold chain on receipt.

General reconstitution guidance (literature; adapt to your SOPs):

• Solvent: Reconstitute in anhydrous DMSO to prepare a concentrated stock (e.g., 10–50 mM). If moisture-sensitive, use dry solvent and handle under inert gas.
• Aliquoting: Divide into single-use aliquots in solvent-resistant vials or plates to avoid repeated freeze–thaw.
• Working solutions: Dilute into pre-warmed assay medium or buffer with thorough mixing to minimize precipitation; keep final DMSO low (commonly ≤0.1–0.5% v/v).
• Short-term handling: Keep on ice during setup; minimize room-temperature exposure and light if stability data are limited.
• Long-term storage: For maximum stability, store sealed aliquots at -80°C. Document preparation date and nominal concentration; consider periodic QC (e.g., LC-MS) for long studies.

Item-specific stability, solubility limits, and degradation pathways are not provided here; consult the CoA/SDS and verify empirically in your system.

Structure and Identity

Product name: Ro-3306 (SKU: R408011)

• CAS: 872573-93-8
• PubChem CID: 135400873
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.
• InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.

Structural features (general, literature/context):

• Ro-3306 is a small-molecule, ATP-competitive kinase inhibitor chemotype used as a selective tool compound in cell-cycle research (literature).
• Functional-group level description (literature context): typically contains aromatic scaffolds and heteroatom donors/acceptors arranged to engage the hinge region of cyclin-dependent kinases via hydrogen bonding and hydrophobic contacts.

2D structural description in words (literature, non-spec item):

• Polycyclic aromatic/heteroaromatic core bearing amide/urea-like H-bonding motifs and hydrophobic substituents consistent with CDK hinge-binding inhibitors. Exact atom connectivity for this catalog item is not specified here; consult the CoA/SDS or public databases for definitive structure.

Synthetic Utility

Ro-3306 is a finished bioactive probe, not typically employed as a synthetic intermediate or building block.

• Functional handles: While heteroatoms in kinase inhibitors can, in principle, undergo derivatization, Ro-3306 is generally used as received for biological testing rather than as a scaffold for SAR in routine synthesis workflows.
• Retrosynthetic value: Limited for general organic synthesis; medicinal chemistry programs would start from known CDK1 inhibitor templates rather than from purchased Ro-3306 as a reagent.
• Recommended practice: Use this compound as a tool/control in assays. For chemical derivatization or prodrug design, consult primary literature for CDK1 inhibitor SAR and synthesize from disclosed intermediates.

If you require a functionalized analog or building-block variant, please inquire about custom synthesis rather than attempting to repurpose this item.

Target Specificity

Not specified for this item; refer to CoA/Spec Sheet.

Note: This section is limited to product-specific data. While Ro-3306 is widely discussed in literature, any claims about targets, selectivity, or cross-reactivity are not provided here for this specific lot and should be verified from authoritative sources.